APO RESEARCH · REPORT
Pertussis Vaccine
Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.
Product & engineering
Understand the product.
Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.
Selected research
Industry Research
Pertussis Vaccine Industry Research Report 2026
Market perspective
Pertussis vaccine is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.
Global pertussis vaccine key players include Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, Wuhan Institute of Biological Products, Walvax Biotechnology etc. Global top 2 manufacturers hold a share about 90%. Europe is the largest market, with a share over 30%, followed by North America.
Report Scope
Read the full market overview
This report quantifies the global Pertussis Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pertussis Vaccine Market by Company
Sanofi Pasteur
GSK
Mitsubishi Tanabe Pharma
Wuhan Institute of Biological Products
Walvax Biotechnology
Minhai Biotechnology
KM Biologics
Chengdu Institute of Biological Products
Pertussis Vaccine Segment by Type
Whole-cell Vaccines
Acellular Vaccines
Pertussis Vaccine Segment by Application
12 Months Below
12 Months Above
Pertussis Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pertussis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pertussis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pertussis Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pertussis Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pertussis Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pertussis Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Whole-cell Vaccines
- Acellular Vaccines
Applications
- 12 Months Below
- 12 Months Above
Companies covered
- Sanofi Pasteur
- GSK
- Mitsubishi Tanabe Pharma
- Wuhan Institute of Biological Products
- Walvax Biotechnology
- Minhai Biotechnology
- KM Biologics
- Chengdu Institute of Biological Products
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pertussis Vaccine Market Size (2021-2032)
- 2.2.2 Global Pertussis Vaccine Sales (2021-2032)
- 2.2.3 Global Pertussis Vaccine Market Average Price (2021-2032)
- 2.3 Pertussis Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Whole-cell Vaccines
- 2.3.3 Acellular Vaccines
- 2.4 Pertussis Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 12 Months Below
- 2.4.3 12 Months Above
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pertussis Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pertussis Vaccine Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global Pertussis Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Pertussis Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Pertussis Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pertussis Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pertussis Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Pertussis Vaccine, Established Date
- 3.9 Global Pertussis Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi Pasteur
- 4.1.1 Sanofi Pasteur Company Information
- 4.1.2 Sanofi Pasteur Business Overview
- 4.1.3 Sanofi Pasteur Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Pasteur Pertussis Vaccine Product Portfolio
- 4.1.5 Sanofi Pasteur Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Pertussis Vaccine Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Mitsubishi Tanabe Pharma
- 4.3.1 Mitsubishi Tanabe Pharma Company Information
- 4.3.2 Mitsubishi Tanabe Pharma Business Overview
- 4.3.3 Mitsubishi Tanabe Pharma Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mitsubishi Tanabe Pharma Pertussis Vaccine Product Portfolio
- 4.3.5 Mitsubishi Tanabe Pharma Recent Developments
- 4.4 Wuhan Institute of Biological Products
- 4.4.1 Wuhan Institute of Biological Products Company Information
- 4.4.2 Wuhan Institute of Biological Products Business Overview
- 4.4.3 Wuhan Institute of Biological Products Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Wuhan Institute of Biological Products Pertussis Vaccine Product Portfolio
- 4.4.5 Wuhan Institute of Biological Products Recent Developments
- 4.5 Walvax Biotechnology
- 4.5.1 Walvax Biotechnology Company Information
- 4.5.2 Walvax Biotechnology Business Overview
- 4.5.3 Walvax Biotechnology Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Walvax Biotechnology Pertussis Vaccine Product Portfolio
- 4.5.5 Walvax Biotechnology Recent Developments
- 4.6 Minhai Biotechnology
- 4.6.1 Minhai Biotechnology Company Information
- 4.6.2 Minhai Biotechnology Business Overview
- 4.6.3 Minhai Biotechnology Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Minhai Biotechnology Pertussis Vaccine Product Portfolio
- 4.6.5 Minhai Biotechnology Recent Developments
- 4.7 KM Biologics
- 4.7.1 KM Biologics Company Information
- 4.7.2 KM Biologics Business Overview
- 4.7.3 KM Biologics Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 KM Biologics Pertussis Vaccine Product Portfolio
- 4.7.5 KM Biologics Recent Developments
- 4.8 Chengdu Institute of Biological Products
- 4.8.1 Chengdu Institute of Biological Products Company Information
- 4.8.2 Chengdu Institute of Biological Products Business Overview
- 4.8.3 Chengdu Institute of Biological Products Pertussis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Chengdu Institute of Biological Products Pertussis Vaccine Product Portfolio
- 4.8.5 Chengdu Institute of Biological Products Recent Developments
5 Global Pertussis Vaccine Market Scenario by Region
- 5.1 Global Pertussis Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pertussis Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Pertussis Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Pertussis Vaccine Sales by Region: 2027-2032
- 5.3 Global Pertussis Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Pertussis Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Pertussis Vaccine Revenue by Region: 2027-2032
- 5.4 North America Pertussis Vaccine Market Facts & Figures by Country
- 5.4.1 North America Pertussis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pertussis Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Pertussis Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pertussis Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Pertussis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pertussis Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Pertussis Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pertussis Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pertussis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pertussis Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pertussis Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pertussis Vaccine Market Facts & Figures by Country
- 5.7.1 South America Pertussis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pertussis Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Pertussis Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pertussis Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pertussis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pertussis Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pertussis Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pertussis Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Pertussis Vaccine Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global Pertussis Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Pertussis Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Pertussis Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pertussis Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Pertussis Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pertussis Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Pertussis Vaccine Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global Pertussis Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Pertussis Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Pertussis Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pertussis Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Pertussis Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pertussis Vaccine Value Chain Analysis
- 8.1.1 Pertussis Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pertussis Vaccine Production Mode & Process
- 8.2 Pertussis Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pertussis Vaccine Distributors
- 8.2.3 Pertussis Vaccine Customers
9 Global Pertussis Vaccine Analyzing Market Dynamics
- 9.1 Pertussis Vaccine Industry Trends
- 9.2 Pertussis Vaccine Industry Drivers
- 9.3 Pertussis Vaccine Industry Opportunities and Challenges
- 9.4 Pertussis Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst